[go: up one dir, main page]

TWI560201B - Bi-specific antibodies for treating cancer - Google Patents

Bi-specific antibodies for treating cancer

Info

Publication number
TWI560201B
TWI560201B TW104106663A TW104106663A TWI560201B TW I560201 B TWI560201 B TW I560201B TW 104106663 A TW104106663 A TW 104106663A TW 104106663 A TW104106663 A TW 104106663A TW I560201 B TWI560201 B TW I560201B
Authority
TW
Taiwan
Prior art keywords
treating cancer
specific antibodies
antibodies
cancer
treating
Prior art date
Application number
TW104106663A
Other languages
English (en)
Other versions
TW201546091A (zh
Inventor
Tien Lu Cheng
Chien Han Kao
Steven R Roffler
Yu Cheng Su
Hsin Yi Tung
Bing Mae Chen
Kuo Hsiang Chuang
Original Assignee
Univ Kaohsiung Medical
Academia Sinica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kaohsiung Medical, Academia Sinica filed Critical Univ Kaohsiung Medical
Publication of TW201546091A publication Critical patent/TW201546091A/zh
Application granted granted Critical
Publication of TWI560201B publication Critical patent/TWI560201B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW104106663A 2014-03-03 2015-03-03 Bi-specific antibodies for treating cancer TWI560201B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461946997P 2014-03-03 2014-03-03
US201461946980P 2014-03-03 2014-03-03

Publications (2)

Publication Number Publication Date
TW201546091A TW201546091A (zh) 2015-12-16
TWI560201B true TWI560201B (en) 2016-12-01

Family

ID=54055768

Family Applications (3)

Application Number Title Priority Date Filing Date
TW104106663A TWI560201B (en) 2014-03-03 2015-03-03 Bi-specific antibodies for treating cancer
TW105129506A TWI653244B (zh) 2014-03-03 2015-03-03 雙功能抗體用於修飾聚乙二醇化物質之用途
TW106143533A TWI677506B (zh) 2014-03-03 2015-03-03 雙功能抗體及其用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW105129506A TWI653244B (zh) 2014-03-03 2015-03-03 雙功能抗體用於修飾聚乙二醇化物質之用途
TW106143533A TWI677506B (zh) 2014-03-03 2015-03-03 雙功能抗體及其用途

Country Status (9)

Country Link
US (1) US10188742B2 (zh)
EP (2) EP3126398B1 (zh)
JP (1) JP6447887B2 (zh)
KR (1) KR101971770B1 (zh)
CN (2) CN111499753B (zh)
IL (1) IL247590A0 (zh)
SG (1) SG11201606791YA (zh)
TW (3) TWI560201B (zh)
WO (1) WO2015134411A1 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2767329C2 (ru) 2016-02-06 2022-03-17 Эпимаб Биотерапьютикс, Инк. Иммуноглобулин с тандемными fab-фрагментами и варианты его применения
CA3032430A1 (en) * 2016-08-16 2018-02-22 Epimab Biotherapeutics, Inc. Monovalent asymmetric tandem fab bispecific antibodies
GB201622024D0 (en) * 2016-11-14 2017-02-08 Inventage Lab Inc Apparatus and method for large scale production of monodisperse, microsheric and biodegradable polymer-based drug delivery
US20200140572A1 (en) * 2017-05-23 2020-05-07 Kaohsiung Medical University Conditional internalization of pegylated agents by pretargeting bi-specific peg-binding antibodies for diagnosis and therapy
US11571476B2 (en) 2017-12-11 2023-02-07 Taipei Medical University Anti-tumor/anti-tumor associated fibroblast/anti-hapten trispecific antibodies and use thereof
CN118772287A (zh) 2018-02-08 2024-10-15 豪夫迈·罗氏有限公司 双特异性抗原结合分子和使用方法
CN108588020B (zh) * 2018-03-30 2021-09-14 中国科学院苏州纳米技术与纳米仿生研究所 一种含有硒元素的近红外ii区量子点的新应用
AU2019263850A1 (en) 2018-05-03 2020-11-19 Shanghai Epimab Biotherapeutics Co., Ltd. High affinity antibodies to PD-1 and LAG-3 and bispecific binding proteins made therefrom
WO2020247290A1 (en) * 2019-06-04 2020-12-10 Academia Sinica Ligands targed to epidermal growth factor receptors and compositions for use in treating tumors
CN116615462A (zh) * 2020-11-23 2023-08-18 诺华股份有限公司 抗体构建体的表达技术
WO2025090985A1 (en) * 2023-10-27 2025-05-01 Duke University Compositions comprising chimeric antigen receptors targeting citrullinated vimentin and methods of use thereof
CN117736331B (zh) * 2024-02-04 2024-05-07 南昌大学第一附属医院 一种特异性结合psma胞外段的单克隆抗体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201111510A (en) * 2009-09-17 2011-04-01 Univ Kaohsiung Medical Recombinant nucleotide sequence, cell or vector containing the recombinant nucleotide sequence, recombinant single chain anti-polyethylene glycol membrane antibody encoded thereof and method for using the cell containing the recombinant nucleotide sequen
US20120282280A1 (en) * 2009-07-06 2012-11-08 Birgit Bramlage Bi-specific digoxigenin binding antibodies
TWI386645B (zh) * 2010-07-19 2013-02-21 Univ Kaohsiung Medical 可定量任何聚乙二醇分子與其修飾物之抗聚乙二醇表現細胞

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69638269D1 (de) 1995-06-14 2010-11-18 Univ California Hochaffine humane antikörper gegen tumorantigene
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
PT1735348E (pt) 2004-03-19 2012-07-24 Imclone Llc Anticorpo anti-receptor do factor de crescimento humano
AU2006208226A1 (en) * 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
US20090130776A1 (en) 2005-09-01 2009-05-21 Canon Kabushiki Kaisha Binding protein molecule
EP2091975A4 (en) * 2006-11-21 2013-05-22 Univ California ANTIBODIES TO THE EGFR FAMILY, BICE-SPECIFIC ANTIBODIES TO THE EGFR FAMILY AND METHOD FOR THEIR USE
ES2599172T3 (es) 2007-10-19 2017-01-31 Seattle Genetics, Inc. Agentes de unión a CD19 y usos de éstos
US8227577B2 (en) * 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
JP5491511B2 (ja) 2008-10-07 2014-05-14 ブラッコ・シュイス・ソシエテ・アノニム 抗ポリマー抗体およびそれと結合するリポソームまたは微小胞を含むターゲッティング構築物
BR112013023653A2 (pt) * 2011-03-17 2016-12-13 Univ Ramot anticorpo biespecífico, método de preparação do anticorpo, e composição farmacêutica
EA201400709A1 (ru) * 2011-12-19 2016-08-31 Синиммун Гмбх Молекула биспецифического антитела
TWI716362B (zh) * 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120282280A1 (en) * 2009-07-06 2012-11-08 Birgit Bramlage Bi-specific digoxigenin binding antibodies
TW201111510A (en) * 2009-09-17 2011-04-01 Univ Kaohsiung Medical Recombinant nucleotide sequence, cell or vector containing the recombinant nucleotide sequence, recombinant single chain anti-polyethylene glycol membrane antibody encoded thereof and method for using the cell containing the recombinant nucleotide sequen
TWI386645B (zh) * 2010-07-19 2013-02-21 Univ Kaohsiung Medical 可定量任何聚乙二醇分子與其修飾物之抗聚乙二醇表現細胞

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Park JW et al., Clin Cancer Res. 2002 Apr;8(4):1172-81. *

Also Published As

Publication number Publication date
CN106459211B (zh) 2020-03-10
US20170056523A1 (en) 2017-03-02
EP3126398A1 (en) 2017-02-08
TW201546091A (zh) 2015-12-16
EP3725812A1 (en) 2020-10-21
TWI677506B (zh) 2019-11-21
TW201809010A (zh) 2018-03-16
JP6447887B2 (ja) 2019-01-09
KR101971770B1 (ko) 2019-04-24
CN106459211A (zh) 2017-02-22
SG11201606791YA (en) 2016-09-29
TW201712040A (zh) 2017-04-01
EP3126398A4 (en) 2017-11-01
KR20160131009A (ko) 2016-11-15
IL247590A0 (en) 2016-11-30
EP3126398B1 (en) 2020-07-15
WO2015134411A1 (en) 2015-09-11
CN111499753A (zh) 2020-08-07
CN111499753B (zh) 2022-10-21
JP2017527522A (ja) 2017-09-21
TWI653244B (zh) 2019-03-11
US10188742B2 (en) 2019-01-29
EP3725812B1 (en) 2023-09-27

Similar Documents

Publication Publication Date Title
HUS2500001I1 (hu) Antitestkészítmények daganatkezelésre
IL304252A (en) Cancer treatment methods
IL289947A (en) A method for treating cancer
ZA201703290B (en) Methods for tumor treatment using cd3xcd20 bispecific antibody
IL255569A (en) Methods of treating cancer using anti-ox40 antibodies
SG11201708861VA (en) Methods for treating cancer
PT3063173T (pt) Anticorpos anti-cd38 específicos para o tratamento de cancros humanos
IL247478A0 (en) Bispecific antibodies against her2
IL252716A0 (en) Anti-csf1r antibodies for the treatment of pvns
TWI560201B (en) Bi-specific antibodies for treating cancer
IL256836B (en) Methods for treating cancer using apilimod
IL255022A0 (en) Cancer treatment methods
SG11201605070UA (en) Novel methods for treating cancer
IL255018A0 (en) Cancer treatment methods
GB201413942D0 (en) Peptides useful for treating cancer
IL255016A0 (en) Cancer treatment methods